CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 365 enrolled
Drug / intervention
Fremanezumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05458011
NCT05458011Phase 3Completed
CompareCT.gov

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study With an Open-Label Treatment Period of Fremanezumab Administered Subcutaneously Monthly or Quarterly for the Preventive Treatment of Migraine in Adult Chinese Patients

Teva Branded Pharmaceutical Products R&D, Inc.·interventional·Posted Jul 14, 2022·Updated Nov 26, 2025

In Brief

A Phase 3 clinical trial evaluating Fremanezumab and Placebo for Migraine. Completed, enrolled 365 participants across 29 sites.

Detailed Summary

Primary Objective: To demonstrate the efficacy of fremanezumab administered as monthly and quarterly subcutaneous (sc) injections to adult Chinese participants with migraine. Secondary Objectives: * To further demonstrate the efficacy of fremanezumab administered as monthly and quarterly sc injections. * To evaluate the safety and tolerability of fremanezumab administered as monthly and quarterly sc injections.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesChina
Collaborators--

Timeline

Phase 3CompletedFinished
2023202420252026
First PostedJul 14, 2022
Enrollment StartSep 30, 2022
Primary CompletionJan 31, 2024
Study CompletionJun 13, 2024
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 4.0 years ago

Interventions

Fremanezumabdrug

Pharmaceutical form: solution for injection Route of administration: subcutaneous injection

Placebodrug

Pharmaceutical form: solution for injection Route of administration: subcutaneous injection